Biomea Fusion doses first T2D patient in Phase II of BMF-219; Phase I completed

Biomea Fusion, Inc.

First patient with type 2 diabetes dosed in Phase II portion of COVALENT-111 (Phase I/II) of BMF-219.
Phase I healthy volunteer portion completed; BMF-219 well tolerated with favorable PK/PD profile.
BMF-219 is the first menin inhibitor to reach clinic for type 2 diabetes; aims to restore beta cells.
Initial Phase II data expected in first half of 2023; IND filing with FDA on track for Q4 2022.
Preclinical data showed BMF-219 ability to restore beta cell mass in animal models of T2D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.